SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, today reported positive data from a multicenter clinical study (NCT 04708951) comparing the adenoma detection rate (ADR) of its FDA-cleared G-EYE® balloon technology against ENDOCUFF VISION® (ECV) technology in patients undergoing screening or surveillance colonoscopy. Results from this randomized trial, the first head-to-head comparison of these two colonoscopy mechanical enhancement devices, showed that the ADR, particularly for advanced and large adenomas, was higher for the G-EYE® balloon than for the ECV attachment. Seth Gross, MD, Professor, Department of Medicine at NYU Grossman School of Medicine, Clinical Chief, Division of Gastroenterology and Hepatology at NYU Langone Health, and co-author on the abstract, presented the data in an oral session at ACG 2021, which is taking place October 22-27 in Las Vegas (ACG 2021, Presidential Plenary Session 1, Abstract #S233).
Trending
- Physician hiring, turnover increases after practices acquired by private equity, study finds (Fierce Healthcare)
- Supreme Court Case Could Threaten Free Colorectal Cancer Screenings (AJMC)
- Hospitals line up to sue Blue Cross, opting out of $2.8 bln settlement (Reuters)
- ChatGPT Competes With Surgeons in Patient Q&A (Medscape)
- Richard Peek to serve as president of international gastroenterology group (VUMC)
- Medicare To Reimburse Guardant Health’s Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue (Benzinga)
- Why the Hinge Health IPO is so important for digital health (Second Opinion)
- Nine guideline-based best practices for IBS (AGA)